WO1996022996A1 - Derives de dihydrophenazine - Google Patents
Derives de dihydrophenazine Download PDFInfo
- Publication number
- WO1996022996A1 WO1996022996A1 PCT/JP1996/000128 JP9600128W WO9622996A1 WO 1996022996 A1 WO1996022996 A1 WO 1996022996A1 JP 9600128 W JP9600128 W JP 9600128W WO 9622996 A1 WO9622996 A1 WO 9622996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dihydrophenazine
- strain
- derivative
- streptomyces
- derivatives
- Prior art date
Links
- ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 1,2-dihydrophenazine Chemical class C1=CC=C2N=C(C=CCC3)C3=NC2=C1 ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 0.000 title claims abstract description 59
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 26
- 231100000419 toxicity Toxicity 0.000 claims abstract description 19
- 230000001988 toxicity Effects 0.000 claims abstract description 19
- 241000187747 Streptomyces Species 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 9
- 229960002989 glutamic acid Drugs 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims description 15
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 241000186361 Actinobacteria <class> Species 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 abstract description 5
- 241000233866 Fungi Species 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 229930195712 glutamate Natural products 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- -1 carboxyl dihydrophenazine compound Chemical class 0.000 description 11
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 238000000862 absorption spectrum Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000003323 beak Anatomy 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- WQMLFJWIKARBFW-BKKMTDGVSA-N evomonoside Chemical group O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(CC[C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)O)[C@]3(C)CC1 WQMLFJWIKARBFW-BKKMTDGVSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- DZEBSPTYVVEORB-UHFFFAOYSA-N 1,2-dihydrophenazine-1-carboxylic acid Chemical class C1=CC=C2N=C3C(C(=O)O)CC=CC3=NC2=C1 DZEBSPTYVVEORB-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000013379 molasses Nutrition 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000001791 phenazinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N deuterated acetone Substances [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001446247 uncultured actinomycete Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BBBFYZOJHSYQMW-LGDQNDJISA-N (2s)-2,4-diamino-4-oxobutanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O BBBFYZOJHSYQMW-LGDQNDJISA-N 0.000 description 1
- UQZSVIGPZAULMV-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)[C@@H](N)CC(N)=O UQZSVIGPZAULMV-DKWTVANSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- ORCRKWJDDBPJGP-UHFFFAOYSA-N 3-phenylheptane-1,3-diol Chemical compound CCCCC(O)(CCO)C1=CC=CC=C1 ORCRKWJDDBPJGP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/30—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing heterocyclic ring with at least one nitrogen atom as ring member
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/58—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound through only acyclic carbon atoms to a non-saccharide heterocyclic ring, e.g. bleomycin, phleomycin
Definitions
- the present invention relates to a novel dihydrophenazine derivative, a strain capable of producing the same, and a drug using the same.
- L one Glutamate is a kind of Amino acid Natural constituting the evening protein, known to be force s' has a toxicity to neurons. If a substance having the effect of suppressing glutamate toxicity is obtained, it is expected that the substance can be used as a drug to activate and improve brain metabolism.
- Diseases that may be related to reactive oxygen species include inflammation, rheumatoid arthritis, autoimmune diseases, radiation-induced skin disease, Parkinson's disease, and ischemic heart and brain disorders. If an antioxidant capable of appropriately removing active oxygen can be obtained, it is expected that the antioxidant can be used as a therapeutic agent for these diseases.
- JP-A-64-22861 discloses the following compound produced from a strain shown as Streptomyces ⁇ .
- Tetrahedron Letters, No. 7, 943-946 (1991) discloses the following compounds produced from a strain belonging to Streptomyces ⁇ .
- Said R is H or CH 3.
- the above compound exhibits a function as a radical avenger of radicals such as vitamin E.
- the present inventors have discovered a new actinomycete strain belonging to the genus Streptomyces from soil. This strain has been deposited on December 22, 1994 at the Institute of Biotechnology and Industrial Technology, 1-3-1 Higashi, Tsukuba, Ibaraki, Japan (Accession number: F ERM P-14717). Based on the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for Patent Procedures, it was internationally deposited on January 27, 1995 with the Institute of Biotechnology and the Institute of Biotechnology. The accession number is FERM BP-5303
- the present inventors have conducted research on this strain and found that this strain is capable of producing a novel dihydrophenazine derivative represented by the following formula I or II.
- FIG. 1 is a graph showing the UV-visible absorption ⁇ spectrum of dihydrophenazine derivative I.
- FIG. 2 is a graph showing an infrared absorption spectrum of the dihydrophenazine derivative I.
- FIG. 3 is a graph showing the 'H-NMR spectrum of the dihydrophenazine derivative I.
- FIG. 4 is a graph showing a 13 C-NMR spectrum of the dihydrophenazine derivative I.
- FIG. 5 is a graph showing an ultraviolet-visible absorption spectrum of a dihydrophenazine derivative.
- FIG. 6 is a graph showing an infrared absorption spectrum of the dihydrophenazine derivative.
- FIG. 7 is a graph showing a ⁇ -NMR spectrum of the dihydrophenazine derivative ⁇ .
- FIG. 8 is a graph showing a 13 C-NMR spectrum of a dihydrophenazine derivative.
- FIG. 9 is a micrograph ( ⁇ 100) of the strain.
- FIG. 10 is a micrograph (approximately 120 ⁇ 0 ⁇ ) of the strain.
- FIG. 11 is a graph showing the results of measuring the glutamate toxicity inhibitory action of dihydrophenazine derivative I.
- FIG. 12 is a graph showing the results of measuring the glutamate toxicity inhibitory action of a dihydrophenazine derivative.
- a hydroxyl group at the 1-position of ⁇ -L-rhamnose having a viranose structure is bonded to the carboxyl group of the carboxydihydrophenazine derivative by an s-ester bond.
- This ester bond can be hydrolyzed and recombined. Accordingly, this compound is decomposed into ⁇ -L-rhamnose and a carboxyl dihydrophenazine derivative, and the carboxyl dihydrophenazine derivative, which is a decomposition product, is ester-bonded to another sugar to form another type of dihydrophenazine.
- a nadine derivative can also be synthesized.
- dihydrophenazine derivative I The physicochemical properties of dihydrophenazine derivative I are as follows.
- Shape orange powder Melting point: 63. 0-64. O
- Solubility soluble in methanol, chloroform, dimethyl sulfoxide, and acetone, insoluble in hexane
- FIG. 1 shows an ultraviolet-visible absorption spectrum of the dihydrophenazine derivative I.
- the measurement was performed in methanol and the scanning speed was 120. OnmZ min.
- the band pass is 2. OOnm.
- FIG. 2 shows an infrared absorption spectrum of the dihydrophenazine derivative I.
- the measurement was performed by the KBr tablet method.
- absorption powers derived from a hydroxyl group (3450 cm- 1 ), a secondary amine (3330 cm- 1 ), a ketone (1680 crrr) and an ester (1680 cm- ', 1260 cm-') were observed.
- the figure shows the 'H-NMR spectrum of the dihydrophenazine derivative I. The measurement was performed at 500 MHz in deuterated acetone.
- FIG. 4 shows a 13 C-NMR spectrum of the dihydrophenazine derivative I. The measurements were performed at 500 MHz in heavy acetone.
- the Rf value of the dihydrophenazine derivative I by thin-layer chromatography (cloform form Z methanol-10-1) was 0.42.
- the physicochemical properties of the dihydrophenazine compound are as follows.
- Solubility soluble in methanol, chloroform, dimethyl sulfoxide, and acetone, insoluble in hexane
- FIG. 5 shows an ultraviolet-visible absorption spectrum of the dihydrophenazine compound. The measurement was performed in methanol and the scanning speed was 120. Onm / min. The band pass is 2.00 nm. As shown in FIG. 5, there are absorption peaks at 229 nm (28 900), 245 nm (27400), 296 nm (26000), 367 nm (4000) and 490 nm (1 1700). No change in the absorption beak due to acid and alkali was observed.
- FIG. 6 shows the infrared absorption spectrum of the dihydrophenazine compound. The measurement was performed by the KBr tablet method. In the infrared absorption spectrum, a hydroxyl group (3450 cm- single, secondary Amin (3330Cm- absorption derived was observed in '), a ketone (1680Cnr one and esters (1680crtT l, 1260 cnr') .
- FIG. 7 Shows the 'H-NMR spectrum of dihydrophenazine compound ⁇ . Was performed in heavy acetone at 500 MHz.
- FIG. 8 shows a ' 3 C-NMR spectrum of the dihydrophenazine compound. The measurement was performed at 500 MHz in deuterated acetone.
- the Rf value of the dihydrophenazine compound ⁇ by thin-layer chromatography was 0.42.
- Aerial hyphae form a short main axis, and irregularly long branches, straight or curved, to form 10 to 50 or more spore chains.
- the spores are non-motile, cylindrical or oblong and have a width of 0.5 to 0.8 "m.
- the spore surface is smooth.
- Spores, spores, and other special forms No cell wall chemical type is type I.
- FIGS. 9 100 ⁇
- 10 about 12000 ⁇
- the length of the white bar seen in Fig. 10 is 500nm.
- the strains were (1) sucrose-nitrate agar, (2) glucose-asparagine agar, (3) glycerin-asparagine agar, (4) inorganic salt-starch agar, (5) tyrosine agar.
- the results of culturing on a medium, (6) nutrient agar medium, (7) yeast 'malt agar medium, and (8) oatmeal agar medium are shown.
- Table 1 shows the culture characteristics on the above various media.
- Table 1 Medium Color of the flora on the colony surface Color of the lining of the colony Diffusible dye
- the flora color on the colony surface is a gray series.
- the back color is dark reddish brown and dark brown.
- Diffusible dyes are pale orange to pale red or dark orange. The hues of these dyes did not change with changes in PH.
- Table 2 below shows the physiological properties and the assimilation of carbon sources.
- this strain is mesophilic, and uses glucose, arabinose, xylose, and mannitol as carbon sources assimilating ability. Based on the morphological characteristics and cell wall chemical type of this strain, this strain is located in Streptomyces II.
- Streptomyces purophofuscus Str-marked tomyces purpeofuscus
- Table 3 the properties of this strain and Streptomyces * parvofuscus are based on the assimilation ability of the carbon source ( Except for the mannits).
- Perovskus spore chain form straight or curved + +
- the dihydrophenazine derivatives I and ⁇ of the present invention can be produced by aerobically culturing a production bacterium such as the present strain in a suitable medium and collecting the target substance from the culture.
- the culture medium is composed of nutrient sources available for the dihydrophenazine derivative producing bacteria. Glycerol is preferred as the carbon source.
- Glycerol is preferred as the carbon source.
- molasses, casein and polypeptone force can be preferably used.
- inorganic salts can be added according to the amount of water.
- An appropriate antifoaming agent eg, silicone may be added to suppress foaming during acidification.
- dihydrophenazine derivatives I and II it is preferable to employ aerobic submerged culture conditions. These conditions are the same as the culture conditions for mass production of other ⁇ 3 ⁇ 4 ⁇ -like bioactive substances. For small-scale production, shaking culture in a flask can be employed.
- the cells may be cultured using a jar fermenter.
- vegetative cells of the microorganism for inoculation in the acid fermentation tank in order to avoid growth delay in the production process.
- the culture medium for producing vegetative cells may be different from the culture medium for producing the dihydrophenazine derivatives I and II.
- Agitation and aeration of the culture mixture can be performed in a conventional manner.
- a blower or a similar mechanical stirring device can be used. You may search by rotating or shaking the acid fermentation tank.
- Various bomb devices can be used for ventilation.
- aeration may be performed by passing sterilized air through the medium.
- the acid fermentation temperature is generally from 10 to 40 ° C, preferably from 20 to 30 ° C.
- the fermentation time is generally 50 to 200 hours. The acid fermentation time varies depending on the acid fermentation conditions and scale.
- dihydric phenazine derivatives I and ⁇ ⁇ can be recovered from the culture solution by various conventional recovery and purification methods.
- recovery method solvent extraction, chromatography, or recrystallization can be employed.
- solvent extraction and recrystallization an appropriate solvent is used for each of the dihydrophenazine derivatives I and ⁇ . Two or more solvents may be used in combination.
- the dihydrophenazine derivatives I and ⁇ are generally found in cultured bacterial cell components. Thus, extracts and whether we microbial cells obtained by the culture solution was centrifuged or ⁇ a suitable solvent, it forces s preferred to implement the purification treatment dihydro Hue phenazine derivatives.
- the solvent acetone or methanol can be used.
- Purification of the dihydrophenazine derivatives I and II can be performed by treating the extract in accordance with a conventional method. For example, removing the solvent from the extract by evaporation or distillation, re-extracting with an appropriate solvent (eg, ethyl acetate), and repeatedly drying to obtain a residue containing the dihydrophenazine derivatives I and ⁇ Can be.
- an appropriate solvent eg, ethyl acetate
- a distilling method such as silica gel chromatography or HPLC separation can be performed to purify the dihydrophenazine derivatives I and ⁇ ⁇ ⁇ , respectively.
- the ability to isolate the dihydrophenazine derivative I and II producing strains from the natural world by the usual method is also important for nonproprietary products other than this strain. Specifically, it can be carried out in the same manner as the method for isolating antibiotic-producing bacteria.
- the strain may be subjected to irradiation or other mutation-inducing treatment to improve the productivity of dihydrophenazine derivatives I and II.
- the dihydrophenazine derivatives I and ⁇ obtained as described above exhibit an inhibitory effect on glutamate toxicity.
- the dihydrophenazine derivatives I and ⁇ also have an antioxidant effect. Therefore, the dihydrophenazine derivatives I and ⁇ of the present invention are useful as inhibitors of glutamic acid toxicity or as antioxidants.
- the inhibitory action of the dihydrophenazine derivative of the present invention on glutamate toxicity is stronger than any of the conventionally known compounds, and the dihydrophenazine derivative I can suppress glutamate toxicity by about 50% at several ⁇ . Glutamic acid toxicity can be suppressed by about 50% with dihydrophenazine derivative ⁇ with more than 10 ⁇ .
- Known compounds having an inhibitory action on glutamate toxicity suppress nerve cell death due to mild cerebral ischemia and activate brain metabolism. Therefore, the dihydrofunadine derivatives I and II of the present invention are also effective as therapeutic agents for cerebral ischemic disorders such as cerebral infarction and cerebrovascular dementia.
- Glutamic acid has been suggested to be toxic by various mechanisms, but it has been implicated in the expression of free radicals such as active oxygen in all systems. For this reason, it is known that antioxidants such as vitamin ⁇ ⁇ ⁇ suppress glutamate toxicity.
- the dihydrophenazine derivative of the present invention also exhibits a similar antioxidant effect. Therefore, the dihydrophenazine derivative of the present invention is also effective as a therapeutic agent for diseases involving active oxygen, such as inflammation, rheumatoid arthritis, and autoimmune diseases.
- the active fractions were collected, concentrated under reduced pressure, applied to a reversed-phase silica gel column (Senshu ODS-SS-1020-T, 50 OmL), and eluted with 90% methanol. The active fraction obtained is concentrated under reduced pressure, and then reverse-phase silica gel column.
- the active fractions were collected and concentrated under reduced pressure, and then applied to a reverse phase silica gel column (Senshu 0DS-SS_1020-T, 50 OmL), and eluted with 90% methanol. After the obtained active fraction was reduced under reduced pressure, HPLC fractionation was performed using a reversed phase silica gel column (Senshu Pak. PEGASIL ODS, diameter 2 Omm ⁇ 25 Omm) in a solvent system of 85% methanol. The activated beak was concentrated under reduced pressure to obtain 3 Omg of the dihydrofunazine derivative of the present invention as a red powder. [Example 3]
- a hybridoma (N18-RE-105 cells) of mouse neuroblast JfiM and rat retinal neurons was used.
- Hybridoma cells were inoculated so that the number of cells became 3 . Twenty-four hours later, 1 OmM glutamic acid and the dihydrophenazine derivative of the present invention were added. After the addition of glutamic acid, the cells were further cultured for 24 hours, and then the lactate dehydrogen lactate (LDH) activity contained in the cells and the medium was measured. Glutamate toxicity was evaluated by calculating the LDH release rate according to the following equation.
- FIGS. 11 and 12 The measurement results of dihydrophenazine derivatives I and ⁇ are shown in FIGS. 11 and 12, respectively. These figures are graphs obtained by blotting the measurement results, where the horizontal axis represents the concentration of the dihydrophenazine compound of the present invention and the vertical axis represents the LDH release rate.
- Microsomes were prepared from male Wistar rat livers according to the method of Ernster, Shimi et al. (Above Cell Biol. 15, 541 (1962)).
- Liver microsomes (protein amount 0.5 mg), 0.2 M Tris-HCl buffer (pH 7.4), 2 mg / mLADP, DMS0 (dimethyl) of test substance (dihydrophenazine derivative I of the present invention) Sulfoxide) solution, and 0.5 mL of the reaction solution containing N ADPH in SmgZmL were incubated at 37 ° C for 1 hour.
- reaction Transfer the container to ice water, immediately add 0.05 mL of 0.5% butylhydroxytoluene-ethanol solution to stop the reaction, and further add 0.1% SDS (sodium dodecyl sulfate) 0.25 mL, 20% 1.75 mL of diacid and 1.5 mL of 0.8% thiobarbituric acid solution (pH 3.5) were added. Transfer the reaction vessel into boiling water,
- the dihydrophenazine derivative of the present invention exhibits a glutamate toxicity inhibitory action and an antioxidant action. Therefore, the dihydrophenazine derivative of the present invention has an effect as a glutamate toxicity inhibitor or an antioxidant.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Dérivés de dihydrophénazine représentés par les formules structurales (I) et (II), obtenus à partir des souches d'actinomycètes du genre Streptomyces déposées auprès d'une autorité internationale de dépôt, et ayant un effet antioxydant et de suppression de la toxicité de l'acide L-glutamique pour les neurones de mammifères.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44959/96A AU4495996A (en) | 1995-01-25 | 1996-01-25 | Dihydrophenazine derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7/30152 | 1995-01-25 | ||
JP3015295A JPH08198888A (ja) | 1995-01-25 | 1995-01-25 | ジヒドロフェナジン誘導体 |
JP7/31482 | 1995-01-27 | ||
JP3148295A JPH08198889A (ja) | 1995-01-27 | 1995-01-27 | ジヒドロフェナジン化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996022996A1 true WO1996022996A1 (fr) | 1996-08-01 |
Family
ID=26368444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/000128 WO1996022996A1 (fr) | 1995-01-25 | 1996-01-25 | Derives de dihydrophenazine |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4495996A (fr) |
WO (1) | WO1996022996A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1159964A2 (fr) | 2000-05-31 | 2001-12-05 | Pfizer Products Inc. | Compositions et methodes pour stimuler la motilité gastrointestinale |
EP0945444A4 (fr) * | 1996-12-03 | 2002-02-06 | Nippon Chemiphar Co | Derives d'acide dihydrophenazinecarboxylique |
KR100412909B1 (ko) * | 2000-08-25 | 2003-12-31 | 한국생명공학연구원 | 뇌신경세포 보호물질 및 그 제조방법 |
WO2007098716A1 (fr) | 2006-02-28 | 2007-09-07 | Centro De Ingeniería Genética Y Biotecnología | Composés analogues aux sécrétagogues peptidiques de l'hormone de croissance et préparations contenant ceux-ci |
EP2457893A1 (fr) | 2004-06-18 | 2012-05-30 | Tranzyme Pharma, Inc. | Intermédiaires pour des modulateurs macrocycliques du récepteur de ghréline |
EP2644618A1 (fr) | 2007-02-09 | 2013-10-02 | Tranzyme Pharma, Inc. | Intermédaires dans la synthese de modulateurs macrocycliques du récepteur de la ghréline |
KR20170042123A (ko) * | 2015-10-08 | 2017-04-18 | 한국과학기술연구원 | 페나진 유도체를 포함하는 신경세포 보호용 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06135982A (ja) * | 1992-07-27 | 1994-05-17 | Kirin Brewery Co Ltd | 新規生理活性物質hr04 |
-
1996
- 1996-01-25 AU AU44959/96A patent/AU4495996A/en not_active Abandoned
- 1996-01-25 WO PCT/JP1996/000128 patent/WO1996022996A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06135982A (ja) * | 1992-07-27 | 1994-05-17 | Kirin Brewery Co Ltd | 新規生理活性物質hr04 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0945444A4 (fr) * | 1996-12-03 | 2002-02-06 | Nippon Chemiphar Co | Derives d'acide dihydrophenazinecarboxylique |
EP1159964A2 (fr) | 2000-05-31 | 2001-12-05 | Pfizer Products Inc. | Compositions et methodes pour stimuler la motilité gastrointestinale |
KR100412909B1 (ko) * | 2000-08-25 | 2003-12-31 | 한국생명공학연구원 | 뇌신경세포 보호물질 및 그 제조방법 |
EP2457893A1 (fr) | 2004-06-18 | 2012-05-30 | Tranzyme Pharma, Inc. | Intermédiaires pour des modulateurs macrocycliques du récepteur de ghréline |
EP2457925A1 (fr) | 2004-06-18 | 2012-05-30 | Tranzyme Pharma, Inc. | Procédé pour la préparation d'un modulateur macrocyclique du récepteur de ghréline et intermédiaires |
WO2007098716A1 (fr) | 2006-02-28 | 2007-09-07 | Centro De Ingeniería Genética Y Biotecnología | Composés analogues aux sécrétagogues peptidiques de l'hormone de croissance et préparations contenant ceux-ci |
EP2644618A1 (fr) | 2007-02-09 | 2013-10-02 | Tranzyme Pharma, Inc. | Intermédaires dans la synthese de modulateurs macrocycliques du récepteur de la ghréline |
KR20170042123A (ko) * | 2015-10-08 | 2017-04-18 | 한국과학기술연구원 | 페나진 유도체를 포함하는 신경세포 보호용 조성물 |
KR101908454B1 (ko) | 2015-10-08 | 2018-10-17 | 한국과학기술연구원 | 페나진 유도체를 포함하는 신경세포 보호용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
AU4495996A (en) | 1996-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KIM et al. | Benzastatins A, B, C, and D: new free radical scavengers from Streptomyces nitrosporeus 30643 I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities | |
JPH03201992A (ja) | 免疫抑制剤の新規な製造方法 | |
KR20020048927A (ko) | 마이크로모노스포라를 이용한 콤팩틴의프라바스타틴으로의 히드록시화 | |
WO1996022996A1 (fr) | Derives de dihydrophenazine | |
JPH10130269A (ja) | カルボリン誘導体 | |
DE69839248T2 (de) | VERFAHREN FÜR DIE HERSTELLUNG VON INHIBITOREN DER HMG-CoA-REDUKTASE. | |
Komiyama et al. | Louisianins A, B, C and D: Non-steroidal growth inhibitors of testosterone-responsive SC 115 cells I. Taxonomy, fermentation, isolation and biological characteristics | |
JPH08198888A (ja) | ジヒドロフェナジン誘導体 | |
JPH02150273A (ja) | 新規なモエノマイシン分解微生物および分解方法 | |
WO2000053792A1 (fr) | Substances wk-5344a et wk-5344b et leur procede de production | |
JPS61265097A (ja) | 発酵法によるメナキノン−4の製造法 | |
JP2862986B2 (ja) | ジテルペン化合物およびその製造法 | |
JPH0625277A (ja) | 新規テストステロン−5α−レダクターゼ阻害物質SNA−4606産生菌、新規テストステロン−5α−レダクターゼ阻害物質SNA−4606及びその製造法 | |
US5118882A (en) | Streptenols from streptomycetes, and the preparation and use thereof | |
JPH08198889A (ja) | ジヒドロフェナジン化合物 | |
JP3796539B2 (ja) | グリセロ糖脂質の製造方法及びそれに用いる微生物 | |
USRE29163E (en) | 1,2,3,4,10,19-Hexanor-9-oxo-5,9-seco-25D-spirostan-5-oic acid | |
JP2786267B2 (ja) | 新規物質dc116 | |
JP2854671B2 (ja) | 新規物質ucf1 | |
JPH05331181A (ja) | ファルネシルトランスフェラーゼ阻害物質oh−4652物質およびその製造法 | |
JP3892427B2 (ja) | ヒドロキシクエン酸の製造方法 | |
JP2766351B2 (ja) | 新規物質dc114―c | |
JPH0378106B2 (fr) | ||
JPH08283241A (ja) | カルバゾール誘導体 | |
WO1999024439A1 (fr) | Nouvelle substance ft-0554 et procede de fabrication |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BB BG BR CA CN CZ EE FI GE HU IS KG KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UG US UZ VN AZ BY KG KZ RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |